ABBVON

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection.

NumeABBVON

PozițieNo.3328

Capitalizare de piață$0.00

Capitalizare de piață complet diluată$0.00

Cotă de piață%

Volum de tranzacționare/capitalizare de piață (24 h)779,567.11%

Ofertă află în circulație137.04226633

Ofertă maximă0

Ofertă totală137.04226633

Rată de circulație%

Data emiterii--

Prețul la care activul a fost emis pentru prima dată--

Maxim dintotdeauna237.64005999136555,2026-03-05

Cel mai mic preț193.3720963640878,2026-04-29

Lanț de blocuri publicETH

IntroducereAbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection.

Sector

Rețele sociale

• Pagină de internet oficială
• Explorator de blocuri

etfindex:mc_etfindex_sourceDeclarație de declinare a responsabilității: Datele sunt furnizate de cmc și nu trebuie considerate drept consultanță pentru investiții.